TNBC, a subtype characterized by the absence of ER, PR, and HER2 expression, poses challenges in treatment due to the lack of targeted therapies typically effective against hormone receptor-positive or HER2-positive breast cancers.[34] Studies investigating the association between breastfeeding and TNBC risk have shown mixed results. This evidence concerns the gene NR4A1 and breast cancer.